21 results
8-K
EX-99.1
LGVN
Longeveron Inc - Ordinary Shares
20 Jul 23
Longeveron Appoints Lisa Locklear as Chief Financial Officer
8:30am
will be vital as we continue advancing our innovative cellular therapy assets toward important milestones,” said Wa’el Hashad, Longeveron CEO. “We are excited
DEF 14A
LGVN
Longeveron Inc - Ordinary Shares
13 May 22
Definitive proxy
4:10pm
: SNGX)), VP of Business Development & Operations at Heart Genomics, and Director of Clinical Affairs at Innovative Drug Delivery Systems. Early in his
424B3
luy7uo47896k3ui
22 Dec 21
Prospectus supplement
5:07pm
10-K
hsu4qz
30 Mar 21
Annual report
4:51pm
424B4
4jh2c1br08e
12 Feb 21
Prospectus supplement with pricing info
4:09pm
S-1
EX-10.10
2dy3utoa4qm
19 Jan 21
IPO registration
5:21pm
S-1
5lccqy 7c
19 Jan 21
IPO registration
5:21pm
S-1
EX-10.8
jehowhciw5 qhcnpez
19 Jan 21
IPO registration
5:21pm
S-1
EX-10.9
m2r269
19 Jan 21
IPO registration
5:21pm
DRS/A
EX-10.9
xzlgf5
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
9s48m841k27v
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.10
28bg0jl
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.8
if1ef
30 Dec 20
Draft registration statement (amended)
12:00am